Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshi Alumkal

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisoneCharles J Ryan, Mark Rosenthal, Siobhan Ng, et al.
Epigenetics|September 28, 2011
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancerJacob Schwartzman, Solange Mongoue-Tchokote, Angela Gibbs, et al.
Plos One|March 15, 2014
Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancerLiang Kee Goh, Natalia Liem, Aadhitthya Vijayaraghavan, et al.
Lancet (London, England)|April 20, 2010
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher, Tomasz M Beer, Celestia S Higano, et al.
Nature Cancer|July 14, 2021
Accelerating precision medicine in metastatic prostate cancerJoaquin Mateo, Rana McKay, Wassim Abida, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisoneCharles J Ryan, Mark Rosenthal, Siobhan Ng, et al.
Epigenetics|September 28, 2011
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancerJacob Schwartzman, Solange Mongoue-Tchokote, Angela Gibbs, et al.
Plos One|March 15, 2014
Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancerLiang Kee Goh, Natalia Liem, Aadhitthya Vijayaraghavan, et al.
Lancet (London, England)|April 20, 2010
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher, Tomasz M Beer, Celestia S Higano, et al.
Nature Cancer|July 14, 2021
Accelerating precision medicine in metastatic prostate cancerJoaquin Mateo, Rana McKay, Wassim Abida, et al.
Pageof 2